New test combines both targeted therapy and immune-oncology biomarkers in a single test with 99% actionability, providing benefits for the treatment of patients and the development of new therapies.ASCO, CHICAGO, ILLINOIS – June 1, 2018 – OmniSeq® , a CAP accredited,...
BUFFALO, NEW YORK – April 12, 2018 – OmniSeq® , a molecular diagnostics subsidiary of the Roswell Park Comprehensive Cancer Center, announced today Hitachi High-Technologies Corporation (TOKYO: 8036, Hitachi High-Tech)’s participation in OmniSeq’s Series B financing...
BUFFALO, NEW YORK – April 16, 2018 – OmniSeq®, a molecular diagnostics subsidiary of the Roswell Park Comprehensive Cancer Center, and LabCorp® (NYSE: LH), a leading global life sciences company, announced today the commercial launch of OmniSeq MSI NGS, a tumor-only,...
June 3-7 | Chicago, I Join us @ASCO 2022. LAG3 transcriptomic expression correlates with high levels of PD-1, PD-L1, PD-L2, and CTLA-4 checkpoints and with high tumor mutational burden across cancers.
Sunday, June 5, 8-11:00 AM CDT
June 3-7 | Chicago, IL Join us at the @ASCO 2022. Comprehensive transcriptomic analysis of immune checkpoint markers in a pan-cancer cohort: Implications for response and resistance.
#376244-Developmental Therapeutics—Immunotherapy Sunday, June 5, 2022, 8:00 AM -11:00 AM CDT
June 3-7 | Chicago, IL Join us at the 2022 ASCO Annual Meeting.
Comprehensive genomic and immune profiling defines immunotherapy treatment in NSCLC patients with low PD-L1 IHC.
#2623 -Developmental Therapeutics—Immunotherapy
Sunday, June 5, 2022, 8:00 AM -11:00 AM CDT
Last year, the Buffalo-based cancer diagnostics firm @OmniSeq quietly was acquired by one of the world's largest life science companies, @Labcorp . Developing molecular diagnostic tests for cancer patients, OmniSeq is looking to scale its operations.